Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]

TULIKIVI CORPORATION STOCK EXCHANGE RELEASE 24 APRIL 2025 AT 2:00 P.M. EEST The annual remuneration of each member of the Board of Directors is EUR 22,000. The annual remuneration shall be paid in the form of Series A shares in Tulikivi Corporation so that the shares are purchased on the stock exchange by 31 December 2025. The company will acquire shares from the market on behalf of, or transfer the company's own shares held by the company to, the board members. The company will bear the costs of acquiring ...